Artykuły w Czytelni Medycznej o SARS-CoV-2/Covid-19

Zastanawiasz się, jak wydać pracę doktorską, habilitacyjną lub monografię? Chcesz dokonać zmian w stylistyce i interpunkcji tekstu naukowego? Nic prostszego! Zaufaj Wydawnictwu Borgis – wydawcy renomowanych książek i czasopism medycznych. Zapewniamy przede wszystkim profesjonalne wsparcie w przygotowaniu pracy, opracowanie dokumentacji oraz druk pracy doktorskiej, magisterskiej, habilitacyjnej. Dzięki nam nie będziesz musiał zajmować się projektowaniem okładki oraz typografią książki.

Poniżej zamieściliśmy fragment artykułu. Informacja nt. dostępu do pełnej treści artykułu tutaj
© Borgis - Nowa Medycyna 6/2002
Marta Wysocka
Wyniszczenie nowotworowe – przegląd możliwości terapeutycznych
Cancer cachexia – review of therapeutic approaches
z Kliniki Diabetologii Diecięcej i Wad Wrodzonych II Katedry Pediatrii Akademii Medycznej w Warszawie
Kierownik Katedry i Kliniki: prof. dr hab. Lech Korniszewski
Streszczenie
Cancer cachexia is common clinical problem that substantially impacts upon the quality of life and survival of affected patients. It is the result of major metabolic changes produced by tumor-released substances as well as by cytokines and some endogenous peptides. Cachexia should be suspected in patients with cancer if an involuntary weight loss of grater than five percent of premorbid weight occurs within a six-month period. Aggressive parenteral nutrition has not been able to increase patients survival or produce any significant symptomatic improvement. Despite positive pilot trial reports, large randomized studies have been unable to demonstrate a clinically defensible role for either pentoxifylline, serotonin, or hydrazine for patients with anorexia. Corticosteroids have been shown to increase appetite for a brief period of time, but they do not appear to improve caloric intake or nutritional status. In comparison, multiple studies have demonstrated that the progestational agent, megestrol acetate, has both appetite-enhancing and weight-promoting properties. A new approach to the management of cachexia has been to combine the appetite-stimulating properties of a progestational agent with the anti-inflammatory properties of the NSAIDs by using megestrol and ibuprofen together.

Powyżej zamieściliśmy fragment artykułu, do którego możesz uzyskać pełny dostęp.

Płatny dostęp do wszystkich zasobów Czytelni Medycznej

Aby uzyskać płatny dostęp do pełnej treści powyższego artykułu oraz WSZYSTKICH około 7000 artykułów Czytelni, należy wprowadzić kod:

Kod (cena 30 zł za 30 dni dostępu) mogą Państwo uzyskać, przechodząc na tę stronę.
Wprowadzając kod, akceptują Państwo treść Regulaminu oraz potwierdzają zapoznanie się z nim.

Piśmiennictwo
1. Barber M.: Advances in the Management of Tumor-Induced Weight Loss, www.medscape.com. 2. Inagaki J. et al.: Causes of death in cancer patients. Cancer, 1974, 33:568-573. 3. Evans W. et al.: A randomized trial of oral nutritional support versus ad lib nutritional intake during chemotherapy for advanced colorectal and non-small-cell lung cancer. J. Clin. Oncol., 1987, 5:113-124. 4. Ovesen L. et al.: Effect of dietary counseling on food intake, body weight, response rate, survival and quality of life in cancer patients undergoing chemotherapy: a prospective, randomized study. J. Clin. Oncol., 1993, 11:2043-2049. 5. American College of Physicians: Parenteral nutrition in patients receiving cancer chemotherapy. Ann. Intern. Med., 1989, 110:734-736. 6. Veterans Affair Total Parenteral Nutrition Cooperative Study Group: Perioperative total parenteral nutrition in surgical patients. N. Engl. J. Med., 1991, 325:525-532. 7. Sandstrom R. et al.: The effect of postoperative intravenous feeding (TPN) on outcome following major surgery evaluated in a randomized study. Ann. Surg., 1993, 217:185-195. 8. Brennan M.F. et al.: A prospective randomized trial of total parenteral nutrition after pancreatic resection for malignancy. Ann. Surg., 1994, 220:436-444. 9. Loprinzi C. et al.: Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J. Natl. Cancer Inst., 1990, 82:1127-1132. 10. Bruera E. etal.: A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status and other symptoms in patients with advanced cancer. Cancer, 1990, 66:1279-1282. 11. Filiu J. et al.: Usefulness of megestrol acetate in cancer cachexia and anorexia. A placebo controlled study. Am. J. Clin. Oncol., 1992, 15:436-440. 12. Tchekmedyian N. et al.: Megestrol acetate in cancer anorexia and weight loss. Cancer, 1992, 69:1268-1274. 13. Mantovani G. et al.: Managing cancer-related anorexia/cachexia. Drugs, 2000, 61:499-514. 14. Bruera E. et al.: Effectiveness of megestrol acetate in patients with advanced cancer: a randomized, double-blind, crossover study. Cancer Prev. Control., 1998, 2:74-78. 15. Gebbia V. etal.: Prospective randomised trial of two dose levels of megestrol acetate in the management of anorexia-cachexia syndrome in patients with metastatic cancer. Br. J. Cancer, 1996, 73:1576-1580. 16. Mantovani G. et al.: Megestrol acetate in neoplastic anorexia/cachexia: clinical evaluation and comparison with cytokine levels in patients with head and neck carcinoma treated with neoadjuvant chemotherapy. In. J. Clin. Lab. Res., 1995, 25:135-141. 17. De Conno F. et al.: Megestrol acetate for anorexia in patients with far-advanced cancer: a double-blind controlled clinical trial. Eur. J. Cancer, 1998, 34:1705-1709. 18. Buntzel J., Kuttner K.: Value of megestrol acetate in the treatment of cachexia in head-neck tumors. Laryngolorhinologie, 1995, 74:504-507. 19. Azcona C. et al.: Megestrol acetate therapy for anorexia and weight loss in children with malignant solid tumors. Aliment Pharmacol. Ther., 1996, 10:577-586. 20. Loprinzi C. etal.: Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for treatment of cancer anorexia/cachexia. J. Clin. Oncol., 1999, 17:3299-3306. 21. Jatoi A. et al.: Dranabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J. Clin. Oncol., 2002, 20:567-573. 22. Basaria S. et al.: Anabolic-androgenic steroid therapy in the treatment of chronic diseases. J. Clin. Endocrin. Metab., 2001, 86:5108-5117. 23. Kardinal C. et al.: A controlled trial of cyproterone in cancer patients with anorexia and/or cachexia. Cancer, 1990, 65:2657-2662. 24. Goldberg R. et al.: Pentoxyfilline for treatment of cancer anorexia and cachexia? A randomised, double-blind, placebo-controlled trial. J. Clin. Oncol., 1995, 13:2856-2859. 25. Loprinzi C. et al.: Randomised placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer. J. Clin. Oncol., 1994, 12:1121-1125. 26. Loprinzi C. et al.: Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer. J.Clin. Oncol., 1994, 12:1126-1125. 27. Lissoni P. et al.: Is there a role for melatonin in the treatment of neoplastic cachexia? Eur. J. Cancer, 1996, 32A:1340-1343. 28. Lundholm K. et al.: Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res., 1994, 54:5602-5606. 29. McMillan D. et al.: Effect of extended ibuprofen administration on the acute phase protein response in colorectal cancer patients. Eur. J. Surg. Oncol., 1995, 21:531-534. 30.McMillan D. et al.: Apilot study of megestrol acetate and ibuprofen in the treatment of cachexia in gastrointestinal cancer patients. Br. J. Cancer., 1997, 76:788-790. 31.McMillan D. et al.: A prospective randomised study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. Br. J. Cancer, 1999, 79:495-500. 32. Wigmore S. et al.: The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. Nutrition, 1996, 12(supl.1):S27-S30. 33.Wigmore S. et al.: Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer. Nutr. Cancer, 2000, 36:177-184. 34.Gogos C. et al.: Dietary omega-3 polyunsaturated fatty acids plus vitamin E restore immunodeficiency and prolong survival for severely ill patients with generalized malignancy. A randomised controlled trial. Cancer, 1998, 82:395-402.
Nowa Medycyna 6/2002
Strona internetowa czasopisma Nowa Medycyna